Archive for the ‘Arthritis’ Category

FDA Approves Orencia(R) (abatacept) For Moderate-To-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) In Patients Over Six

Wednesday, April 9th, 2008

Bristol-Myers Squibb Company (NYSE: BMY)today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA® (abatacept) for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used as monotherapy or concomitantly with methotrexate ...

ACZ885, A New Biological Drug In Development, Shows Potential In Treating Serious Life-long Autoinflammatory Diseases

Wednesday, April 9th, 2008

New data demonstrate that ACZ885, a human monoclonal antibody in Phase III development, achieves long-lasting clinical remission in patients with genetic autoinflammatory diseases1,2. The results indicate that ACZ885 could develop into a major therapeutic advance in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare but serious life-long ...

Hit Pain Where It Hurts: Arthritis Care Launches New UK Course

Tuesday, April 8th, 2008

Time to take your life back - that's Arthritis Care's message to 7.8 million* people in the UK who live with chronic day-to-day pain. The 61-year old charity today marks its awareness week (12th-18th April) by launching its new Challenging Pain programme across the country.. Around half of those living ...

Current And Emerging Drugs Have No Advantage Over Enbrel In Inhibiting/Slowing The Progression Of Rheumatoid Arthritis

Tuesday, April 8th, 2008

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on inhibiting/slowing the progression of structural damage and reducing the signs and symptoms of rheumatoid arthritis during the first year of treatment are the attributes that ...

Can-Fite: First Patient Was Enrolled To The Phase IIb Rheumatoid Arthritis Trial

Thursday, April 3rd, 2008

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, reports that a confirmatory Phase IIb trial is now enrolling patients as part of the ongoing development of CF101. The regulatory process in which the Company was involved during the past few months resulted in approvals for ...

Neurochem Withdraws Its Marketing Authorisation Application For Kiacta(eprodisate Disodium), Europe

Tuesday, March 25th, 2008

The European Medicines Agency (EMEA) has been formally notified byNeurochem Luxco II SARL of its decision to withdraw the application fora centralised marketing authorisation for the medicine Kiacta(eprodisate disodium) capsules.Kiacta was expected to be used for the treatment of amyloid Aamyloidosis, a rare, life-threatening disease that occurs in patientswith long-lasting ...

ACTEMRA Significantly Improves Symptoms For Rheumatoid Arthritis Patients Who Did Not Respond Well To Standard Therapy

Thursday, March 20th, 2008

Patients with rheumatoid arthritis treated with ACTEMRA™ (tocilizumab) experienced a rapid and significant reduction in the signs and symptoms of their disease, according to a study published in this week's issue of The Lancet. Results from the OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial a ...

What Causes Rheumatoid Arthritis - How Is Your Heart Affected?

Wednesday, March 19th, 2008

In a recent issue of The Johns Hopkins Arthritis Bulletin, Johns Hopkins specialists reported on the latest research regarding the link between rheumatoid arthritis and heart health. With rheumatoid arthritis, the inflammation that damages joints also takes a toll on the heart. Johns Hopkins specialists offer bottom line advice on ...

Fibromyalgia Pain And Changes In Brain Molecule Linked

Tuesday, March 11th, 2008

Researchers at the University of Michigan Health System have found a key linkage between pain and a specific brain molecule, a discovery that lends new insight into fibromyalgia, an often-baffling chronic pain condition.In patients with fibromyalgia, researchers found, pain decreased when levels of the brain molecule called glutamate went down. ...

New Study Finds MRI Unnecessary For Diagnosing Osteoarthritis Of The Knee

Tuesday, March 11th, 2008

Osteoarthritis (OA) is known as the "wear and tear" arthritis, effecting millions of people. Patients seeking relief from this disease are often sent for a magnetic resonance image (MRI) to diagnose their problem. A new study revealed today at the 75th Annual Meeting of the American Academy of Orthopaedic Surgeons ...